Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.

Calreticulin (CALR) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2-inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation.

Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a F-2-fluoro-2-deoxy-D-glucose-positron emission tomography study.

Purpose: To assess the brain metabolic correlates of the different regional extent of ALS, evaluated with the King's staging system, using brain F-2-fluoro-2-deoxy-D-glucose-PET (F-FDG-PET).

Methods: Three hundred ninety ALS cases with King's stages 1, 2, and 3 (n = 390), i.e.

A New Formulation of an Old Drug: A Potential New Therapy in the Management of Oral cGvHD.

Oral chronic graft versus host disease (cGVHD) is often refractory to systemic therapies. Additional topical treatment is commonly required. The potency of the agent, the vehicle and formulation in which it is delivered are all critical factors in determining the effectiveness of topical therapies.

[Paleobiology in the population of Herculaneum (79 A.D].

The anthropologic examination of the human skeletal remains recovered on the ancient beach of Herculaneum provides a unique opportunity for gaining paleobiological data on a Roman population. The eruption caught the people on the ancient beach as they were trying to escape; the volcanic surges and pyroclastic flows had different effects on them depending upon where they were on the beach. Those caught in the open suffered immediate dehydratation, with cranial explosion and complete burning of bones, whereas those trapped in the boat sheds suffered slower dehydration.